SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 228793.
  • 2
    Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 38793.
  • 3
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 227585.
  • 4
    Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 12434.
  • 5
    Dixon WG, Suissa S, Hudson H. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 2011; 13: R139.
  • 6
    Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006; 54: 3399407.
  • 7
    Ontario Ministry of Health and Long-Term Care. Ontario Health Insurance Plan: the program. 2008. URL: http://www.health.gov.on.ca/en/public/programs/ohip/.
  • 8
    World Health Organization. International Classification of Diseases, Ninth Revision, Clinical Modification. Geneva: World Health Organization; 1979.
  • 9
    Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit: the program. 2008. URL: http://www.health.gov.on.ca/english/providers/program/drugs/odbf_mn.html.
  • 10
    Canadian Institute for Health Information. The CIHI Data Quality Framework. Ottawa (ON): CIHI; 2009.
  • 11
    Institute for Clinical Evaluative Sciences. Improving health care data in Ontario: ICES investigative report. Toronto: ICES; 2005.
  • 12
    Hawker GA, Badley EM, Jaglal S, Dunn S, Croxford R, Ko B, et al. Musculoskeletal conditions. In: Bierman AS, editor. Project for an Ontario Women's Health evidence-based report: volume 2. Toronto: St. Michael's Hospital and Institute for Clinical Evaluative Sciences; 2010. p. 1198.
  • 13
    Widdifield J, Bernatsky S, Paterson JM, Thorne JC, Cividino A, Pope J, et al. Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. Arthritis Care Res (Hoboken) 2011; 63: 537.
  • 14
    Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 115760.
  • 15
    Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007; 57: 14318.
  • 16
    Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 23319.
  • 17
    Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 175464.
  • 18
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 6139.
  • 19
    Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 2004; 57: 128894.
  • 20
    Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 85464.
  • 21
    Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002; 25: 5126.
  • 22
    Hudson M, Suissa S. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62: 80510.
  • 23
    Vinet E, Kuriya B, Widdifield J, Bernatsky S. Rheumatoid arthritis disease severity indices in administrative databases: a systematic review. J Rheumatol 2011; 38: 231825.
  • 24
    Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti–tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 62834.
  • 25
    Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155: 16059.
  • 26
    Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20: 74853.
  • 27
    Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infections in Canada and the United Kingdom. Epidemiol Infect 2001; 127: 30514.
  • 28
    McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48: 136471.
  • 29
    Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006; 45: 13705.
  • 30
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009; 301: 73744.
  • 31
    Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, Rosello R, Hernandez MV, Gomez-Reino JJ, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010; 69: 17515.
  • 32
    Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. F1000 Med Rep 2011; 3: 14.
  • 33
    Tsiodras S, Samonis G, Boumpas D, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor α blockade therapy. Mayo Clin Proc 2008; 83: 18194.
  • 34
    Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294300.
  • 35
    Koetz K, Bryl E, Spickschen K, et al. T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 2000; 97: 92038.
  • 36
    Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 107481.
  • 37
    Moride Y, Abenhaim L. The depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 7317.
  • 38
    Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 191420.
  • 39
    Dixon W, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 95660.
  • 40
    Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in patients with rheumatoid arthritis: a nested case-control analysis using a weighted cumulative dose model. Ann Rheum Dis 2012; 71: 112833.
  • 41
    Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007; 56: 112533.
  • 42
    Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, editor. Pharmacoepidemiology. New York: John Wiley; 2000. p. 785805.
  • 43
    Bernatsky S, Lix L, O'Donnell S, Lacaille D, for the CANRAD Network. Consensus statements for the use of administrative health data in rheumatic disease research and surveillance. J Rheumatol 2012. E-pub ahead of print.
  • 44
    Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009; 61: 3004.
  • 45
    Emery P, Gallo G, Morgan CL, Currie CJ, Poole CD, Nab H. Evaluation of the association between disease activity and risk of serious infections in subjects with rheumatoid arthritis when treated with etanercept or disease-modifying anti- rheumatic drugs [abstract]. Arthritis Rheum 2011; 63 Suppl: S163.